CorInsights MRI
by ADM Diagnostics
· Based in United States →
— See clearly what IMAGING INSIGHTS can reveal for patient care
Contact vendor
Regulatory Status Disclosed
Overview
CorInsights MRI is an FDA-cleared medical image processing software developed by ADM Diagnostics, Inc. It provides quantitative information about brain tissue volume using standard T1-weighted MRI scans. The software measures brain volumes, determines percentiles compared to age- and sex-matched normative values, and identifies patterns of tissue volume loss. This information is translated into a set of images, graphs, and summaries in an illustrated patient-specific report, aiding radiologists, neurologists, and clinical researchers in assessing neurodegenerative conditions like Alzheimer’s disease and other dementias. The analysis is completed securely with a same-day turnaround. CorInsights MRI is intended for adults aged 45 to 95. The product was developed and validated using a curated database of more than 30,000 well-characterized brain images.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automated MRI brain image processing
- Quantitative brain volume measurement
- Comparison to age- and sex-matched normative data
- Generation of annotated images and volumetric reports
- Support for adults aged 45 to 95
- Secure electronic submission of scans
- Same-day turnaround for analysis and reports
- Identification of lowest percentile brain regions
- Patient-friendly graphs for communication
- Requires only a T1-weighted MRI scan
Use Cases
- Aiding in the assessment of Alzheimer's disease
- Diagnosing and monitoring other neurodegenerative diseases
- Differentiating various forms of dementia
- Predicting cognitive decline
- Measuring treatment effect in clinical trials
- Providing quantitative visualization for radiologists
What Physicians Need to Know
Brain MRI Analysis
CorInsights MRI uses standard MRI scans to provide quantitative information about brain tissue volume. It accurately measures brain volume in specific regions and compares this data to a proprietary normative reference database. The software translates these comparisons into images, graphs, and summaries to help medical professionals understand overall patterns of effect. It is intended for adults aged 45 to 95. The software has been tested with scans from 1.5T and 3T MRI scanners from various manufacturers like Siemens, GE, and Philips. CorInsights MRI is a fully automated MR medical image processing software for automatic labeling, visualization, and volumetric quantification of identifiable brain structures from DICOM formatted MR images. The output is a PDF report and a DICOM image showing anatomical structure boundaries. The software has demonstrated high accuracy and reproducibility in measuring brain volumes, including hippocampal, total gray matter, intracranial, and ventricular volumes.
Neurodegenerative Disease Screening
CorInsights MRI provides quantitative information about brain tissue volume, which is often affected by disorders such as Alzheimer's disease and other types of dementia, showing accelerated patterns of tissue volume loss. The software helps differentiate dementias, predict cognitive decline, and measure treatment effects. It compares a patient's brain MRI scan to a curated normative reference database to determine percentiles relative to age- and sex-matched reference values. The reference database consists of cognitively normal individuals aged 42 to 95, confirmed negative for amyloid pathology and other confounding abnormalities. The software has been validated using patient scans with various diagnoses, including cognitively normal, Mild Cognitive Impairment (MCI), MCI converting to Alzheimer's disease (AD), late-onset AD, early-onset AD, bvFTD, svFTD, and PCA.
Physician Tip
CorInsights MRI offers quantitative brain volume analysis, which can be valuable for tracking neurodegenerative disease progression and assessing treatment efficacy. The same-day turnaround for reports allows for timely clinical decision-making. The comprehensive reports, including images, graphs, and summaries, can aid in patient education and communication. The software's ability to compare patient data to a normative database provides a clear percentile ranking, assisting in identifying deviations from healthy brain volumes.
CorInsights MRI accepts standard, reimbursable patient MRI scans submitted electronically. It is designed to integrate with PACS systems and EHR systems.
Details
| Category | Neurology AI, Radiology & Imaging AI |
| Pricing | Contact vendor |
| Deployment | SaaS |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Geriatrics, Neurology, Radiology |
What the Web Says
CorInsights MRI is an FDA-cleared quantitative image analysis software application developed by ADM Diagnostics. It analyzes standard MRI exams to provide quantitative information about brain tissue volume for radiologists, neurologists, and researchers. The software measures brain region volumes, compares them to a normative database, and generates reports with images, graphs, and summaries.
Overall: MixedStrengths
- Provides quantitative information about brain tissue volume from standard MRI exams.
- Compares individual brain volumes to a proprietary normative reference database.
- Generates comprehensive reports with images, graphs, and summaries.
- Results are typically sent back within the same day.
- FDA-cleared for clinical use.
- Aims to enhance objectivity and consistency in dementia diagnosis.
Limitations
- Limited published clinical validation and in-use evaluation in dementia diagnosis.
- Younger companies in this space generally have not published technical validation of their reports.
- Concerns about time and interpretation difficulties have been identified as barriers to the use of such tools.
- Does not include lesion analysis, unlike some predicate devices.
- Systematic reviews indicate a significant evidence gap in the literature regarding clinical validation and workflow integration of these tools.
Based on reviews from: auntminnie.com, yahoo.com, nih.gov, healthaidb.com, researchgate.net, scispace.com, aihealth.review, fda.gov, auntminnieeurope.com, innolitics.com
Last updated: 2026-10-28
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate CorInsights MRI
Press & Coverage
AuntMinnie.com
ADM Diagnostics wins FDA clearance for CorInsights MRI
ADM Diagnostics received FDA clearance for its CorInsights MRI quantitative image analysis software, which provides brain tissue volume information from standard MRI exams for radiologists, neurologists, and researchers.
2021-12
GlobeNewswire
CorInsights MRI Provides Exceptional Insight Using Brain Volume Quantitation
ADM Diagnostics, Inc. announced FDA clearance for CorInsights MRI, software that uses standard MRI scans to provide quantitative information about brain tissue volume, aiding medical professionals in evaluating patients for brain disorders like Alzheimer's disease.
2021-12
theimagingwire.com
ADMdx CorInsights MRI: ADM Diagnostics (ADMdx) announced the launch of its CorInsights MRI software (FDA cleared), which measures regional brain tissue volumes using standard MRI scans, compares volume data against a reference database, and uses the comparisons to produce patient-specific reports.
ADM Diagnostics (ADMdx) launched its FDA-cleared CorInsights MRI software, which analyzes regional brain tissue volumes from standard MRI scans, compares them to a reference database, and generates patient-specific reports.
2021-10
Brain Communications (Oxford University Press)
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in Alzheimer’s disease patients
A peer-reviewed article discusses the use of ADM Diagnostics' CorInsights MRI analysis tool for segmenting MRI scans and producing regional z-scores in a study evaluating relationships between plasma biomarkers, PET scans, cognitive tests, and regional brain volumes in Alzheimer's disease.
2023-03
MarketsandMarkets.com
Diagnostic Imaging Services Market Size, Growth by Procedure (MRI, Ultrasound, CT, X-RAY, Nuclear Imaging, Mammography), Application (OB/Gyn, Pelvic/Abdomen, Cardiology, Oncology, Neurology), Technology, End User (Hospitals, Diagnostic Centers) & Region - Global Forecasts to 2027
A market report notes that ADM Diagnostics, Inc. received FDA approval in December 2021 for CorInsights MRI to extract quantitative information about brain tissue volume for Alzheimer's disease detection, contributing to the growth of the MRI imaging services market.
2022-09
FDA.gov
CorInsights MRI 510(k) Clearance
The FDA granted 510(k) clearance (K193287) for CorInsights MRI on November 20, 2020, indicating it is substantially equivalent to a predicate device for automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images for adults aged 45 to 95.
2020-11
Newswire.com
ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health
ADM Diagnostics, Inc. was awarded a $1.96 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Aging to develop a diagnostic test to detect and differentiate the effects of repeated head impact upon the brain from Alzheimer's disease.
2022-09
Mordor Intelligence
Brain Tumor Diagnostics Market Size, Share & Growth Analysis Report, 2030
A market analysis report highlights the FDA clearance of CorInsights MRI in December 2021, noting its role in providing quantitative brain tissue volume information for radiologists, neurologists, and clinical researchers, thereby propelling market growth.
2025-01
Videos
Product demos, reviews, and walkthroughs for CorInsights MRI.
No videos found. Search YouTube directly
Frequently Asked Questions
CorInsights MRI is an FDA-cleared AI-powered software that analyzes standard brain MRI scans to provide quantitative information about brain tissue volume. This can assist neurologists in assessing and monitoring neurodegenerative disorders like Alzheimer's disease, other dementias, and multiple sclerosis by detecting subtle changes in brain volume that might be difficult to identify with the naked eye.
CorInsights MRI is intended for adults aged 45 to 95. While it provides valuable quantitative data, AI tools are only as effective as the data they are trained on, and the physician's role remains crucial in interpreting the data and making final treatment decisions. Additionally, CorInsights MRI does not include lesion analysis, unlike some predicate devices.
ADM Diagnostics, the company behind CorInsights MRI, emphasizes the use of proprietary software and secure electronic submission for patient scans. While specific details on data privacy compliance for CorInsights MRI are not extensively detailed in the provided information, generally, medical software companies adhere to industry-standard security measures, including physical access controls, firewalls, intrusion detection, and network monitoring to protect personal information.
Yes, several other FDA-cleared AI-powered brain volumetrics software options exist, including NeuroQuant, icometrix icobrain, Quantib ND, Combinostics cNeuro, Neurophet AQUA, and Neuroreader. CorInsights MRI differentiates itself by focusing on quantitative brain tissue volume measurements and comparing them to a proprietary normative reference database. While these tools offer similar functionalities, published studies suggest that regional volumes can differ between packages, so a fresh baseline may be needed if switching tools for longitudinal patient follow-up.
The provided information does not specify the direct pricing structure for CorInsights MRI. However, it does state that a standard, reimbursable patient scan is submitted electronically to ADMdx for analysis. It's important to note that while MRI scans themselves can range from $400 to $3,500 without insurance, and $75 to $500 with insurance, the cost of AI-powered analysis tools like CorInsights MRI would be separate and subject to specific billing and coverage policies.
Suggest an Edit → | Report an issue
| Last Verified: 2026-04-17 | First Added: 2026-04-17